TY - JOUR
AU1 - Danner, Robert L.
AU2 - Eichacker, Peter Q.
AU3 - Doerfler, Martin E.
AU4 - Hoffman, William D.
AU5 - Reilly, Joseph M.
AU6 - Wilson, James
AU7 - MacVittie, Thomas J.
AU8 - Stuetz, Peter
AU9 - Parrillo, Joseph E.
AU1 - Natanson, Charles
AB - Three groups of dogs were given lipid X (0, 1, or 10 mg/kg) every 8 h for sevendoses, starting simultaneously with the intraperitoneal placement of Escherichia coli-containing fibrin clots. All animals developed bacteremia, hypotension, and a pattern of decreased left ventricular ejection fraction characteristic of septic shock (P = .01). Survival rates and survival times were not significantly differentbetweentreatment groups (P>.2). In a similar experiment, higher doses of lipid Xresulted in a significantlydecreased survivaltime compared with concurrent controls (P = .04). Animals receiving lipid X did not differ from controls in serial determinations of temperature, hemodynamic measurements, or laboratory parameters (except serum total protein). Although lipid X has antiendotoxin effects, no benefit could be demonstrated in this antibiotic treated, gram-negative bacillary-infected model of septic shock. These data do not support a therapeutic role for lipid X in the treatment of gram-negative sepsis.
TI - Therapeutic Trial of Lipid X in a Canine Model of Septic Shock
JF - The Journal of Infectious Diseases
DO - 10.1093/infdis/167.2.378
DA - 1993-02-01
UR - https://www.deepdyve.com/lp/oxford-university-press/therapeutic-trial-of-lipid-x-in-a-canine-model-of-septic-shock-E7xJokrk0t
SP - 378
EP - 384
VL - 167
IS - 2
DP - DeepDyve
ER -